CriticalAntiretroviral, HIV protease inhibitor×Atypical antipsychotics
Updated · Methodology
Mechanism
CYP3A4 is the main enzyme that metabolises quetiapine (quetiapine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Atazanavir inhibits this enzyme, so quetiapine levels are expected to rise (atazanavir SmPC, European Medicines Agency, EMA). Atazanavir is taken with ritonavir, which inhibits CYP3A4 more strongly than atazanavir itself (EMA). Ketoconazole, another CYP3A4 inhibitor, increased the quetiapine area under the concentration curve (AUC) 5- to 8-fold (quetiapine SmPC, AEMPS). The documents give no figures for atazanavir.
Symptoms
Higher quetiapine levels can lead to coma (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA). In quetiapine overdose, somnolence and sedation, tachycardia, hypotension and anticholinergic effects have been reported, as well as QT prolongation, seizures, respiratory depression, urinary retention, confusion, delirium, coma and death (quetiapine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Post-marketing reports also describe QT prolongation with quetiapine at therapeutic doses (AEMPS), and atazanavir causes dose-related asymptomatic PR prolongation (EMA). QT and PR prolongation show only on an electrocardiogram (ECG).
Management
The combination is contraindicated. The atazanavir summary of product characteristics (SmPC) lists quetiapine among contraindicated drugs (atazanavir SmPC, European Medicines Agency, EMA), and so does the atazanavir/cobicistat SmPC (EMA). The quetiapine SmPC contraindicates CYP3A4 inhibitors, including human immunodeficiency virus (HIV) protease inhibitors (quetiapine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The contraindication in the atazanavir SmPC does not depend on the regimen. The recommended adult regimen is atazanavir 300 mg with ritonavir 100 mg once daily with food (EMA). The US atazanavir label is less strict. If atazanavir with ritonavir is started in a patient already taking quetiapine, the label advises considering an alternative antiretroviral regimen. If the combination cannot be avoided, reduce the quetiapine dose to 1/6 of the current dose and monitor for quetiapine adverse reactions (atazanavir label, US Food and Drug Administration, FDA). The European SmPCs do not include this option. Use quetiapine with caution together with drugs that prolong the QT interval, especially in older people and in patients with congenital long QT syndrome, congestive heart failure, cardiac hypertrophy, hypokalaemia or hypomagnesaemia (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Reyataz (atazanavir) prescribing information (2024)– DailyMed setid 165cff62-b284-4a27-a65d-9ec8a5bfcdd8, revisión 12/2024, secciones 4 y 7.3
- AEMPS: Ficha técnica: Quetiapina (nº registro 63054), sección 4.3 (2024)– AEMPS, CIMA, nº registro 63054 (Seroquel 25 mg comprimidos recubiertos con película, Cheplapharm), revisión 12/2024, secciones 4.3, 4.4, 4.5, 4.8 y 4.9
- EMA: Ficha técnica: Atazanavir, Reyataz (EU/1/03/267), sección 4.3 (2026)– EMA, Reyataz 300 mg cápsulas (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 03267008, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir/cobicistat, Evotaz (EU/1/15/1025), sección 4.3 (2026)– EMA, Evotaz 300 mg/150 mg comprimidos (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5